Saturday, May 31, 2025
20.8 C
Bengaluru

Is Your Field Force Optimised to Make the Most of Market Growth in Metros?

Summary of Performance of Top 30 Metros in IPM – Dec’24

Overall Market Performance
• The top 30 metros in India contributed 34% to the total IPM (Indian Pharmaceutical Market) sales for MAT (Moving Annual Total) Dec’24.
• These cities grew at a rate of 8.5%, slightly higher than the overall IPM growth of 7.6%.
• The total market value of these 30 metros increased from ₹71,831 Cr (Dec’23) to ₹77,929 Cr (Dec’24), showing a ₹6,098 Cr increase.

Fastest-Growing Markets
• Top 5 fastest-growing metros:
1. Pune (15%)
2. Agra (14%)
3. Lucknow (13%)
4. Nashik (13%)
5. Delhi (12.5%)
Among the six mega metros, Delhi grew the fastest at 12.5%, followed by Chennai (11.6%) and Hyderabad (10.5%).

Growth Trends & Insights
• 13 out of 30 metros grew faster than the IPM growth rate (7.6%), while 17 metros grew at or below the IPM growth rate.
• Cities like Delhi, Hyderabad, Bangalore, and Chennai remain dominant in total market value, with Delhi leading at ₹10,756 Cr.
• Smaller cities like Bhopal (12%) and Nashik (13%) showed strong growth, indicating increasing pharmaceutical demand in Tier-2 cities.

Conclusion

The Indian pharmaceutical market continues to grow robustly, especially in urban centers. While mega metros remain strong contributors, smaller cities like Lucknow, Pune, and Agra are emerging as high-growth markets. The steady expansion of IPM in these metros suggests increasing healthcare accessibility and demand for pharmaceutical products in urban India.

Hot this week

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?

Tata 1mg App Business Model: How does it work...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline,...

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

The Future in Your Palm+Chemistry – Palmistry

The future in your palm - a non-contact wearable...

Topics

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline,...

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

The Future in Your Palm+Chemistry – Palmistry

The future in your palm - a non-contact wearable...

Nimesulide – Nice or Not Nise?

Nimesulide Regulatory Status Worldwide Nimesulide is a non-steroidal anti-inflammatory drug...

MedicinMan Pharma Monitor March 2025

Indian Pharma Top Brands, Therapy & Regional Insights 🏆...

How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies

April 14, 2025  India’s pharmaceutical industry, a global powerhouse, sends...
spot_img

Related Articles

spot_imgspot_img